Blue-Zone granted Canadian patent for central collection of anesthetic gases

Blue-Zone Technologies Ltd. announced that is has been granted an additional patent in Canada for its halogenated hydrocarbon recovery system.

Granted on October 25, 2016, with a 2009 priority date, the patent relates to Blue-Zone’s Centralsorb® Anesthetic Recovery System, which enables recovery of waste anesthetic gases from a central location in a hospital. Earlier this year Blue-Zone announced a similar patent had been granted to it in the United States.
Halogenated anesthetics are very aggressive greenhouse gases and a typical surgery vents 95% of the drugs used into the atmosphere.  In North America, there are approximately 54,000 operating rooms, and annually those rooms can release the CO₂ equivalent to well over two million cars. These toxic gases are stable, seven times heavier than air, tend to linger and amass in the area around a hospital for decades, and are an officially recognized occupational health and safety hazard. Furthermore, the use of anesthetic gases is forecast to grow globally by 10% to 15% per year.

Blue-Zone’s Centralsorb and Deltasorb® systems prevent the release of anesthetic gases by capturing and then reprocessing the halogenated anesthetics. The gases are then extracted, liquefied and used as raw material in the production of new, validated generic anesthetics at Blue-Zone’s facility.

“Our technology enjoys a global profile, and the awarding of this patent reinforces Blue-Zone’s position of worldwide leadership in the halogenated anesthetic gas collection, reclamation, and production sectors. As we are a Canadian company, the Canadian patent grant is extra special for us,” says Dusanka Filipovic, P.Eng., co-inventor of Centralsorb, and founder, vice chair and president of the company.

For more information, visit: www.blue-zone.ca